Calcipotriol/Betamethasone Dipropionate Aerosol Foam for Plaque Psoriasis: A Prospective, Observational, Non-Interventional, Single-Center Study of Patient Adherence and Satisfaction in Daily Use

Background: Psoriasis is a chronic inflammatory disease that has a negative impact on patients' quality of life. Patients with mild–moderate psoriasis can be treated with topical medications, such as the combination drug calcipotriol/betamethasone dipropionate (Cal/BD). Objectives: This s...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Francisco J. Navarro-Triviño, Mario Lozano-Lozano, Ricardo Ruiz-Villaverde
Formato:	article
Lenguaje:	EN
Publicado:	Mattioli1885 2021
Materias:	adherence satisfaction calcipotriol/bethamethasone aersolo foam psoriasis Dermatology RL1-803
Acceso en línea:	https://doaj.org/article/784adb0dd8e64114a30eb4830d985e78
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:784adb0dd8e64114a30eb4830d985e78
record_format	dspace
spelling	oai:doaj.org-article:784adb0dd8e64114a30eb4830d985e782021-11-17T08:27:52ZCalcipotriol/Betamethasone Dipropionate Aerosol Foam for Plaque Psoriasis: A Prospective, Observational, Non-Interventional, Single-Center Study of Patient Adherence and Satisfaction in Daily Use10.5826/dpc.1103a562160-9381https://doaj.org/article/784adb0dd8e64114a30eb4830d985e782021-05-01T00:00:00Zhttp://dpcj.org/index.php/dpc/article/view/1595https://doaj.org/toc/2160-9381 Background: Psoriasis is a chronic inflammatory disease that has a negative impact on patients' quality of life. Patients with mild–moderate psoriasis can be treated with topical medications, such as the combination drug calcipotriol/betamethasone dipropionate (Cal/BD). Objectives: This study investigated the adherence of psoriasis patients to therapy with Cal/BD aerosol foam, as well as their satisfaction with the treatment’s efficacy, safety, and effect on their quality of life. Methods: Patients with mild–moderate plaque psoriasis were eligible to participate in this open-label, non-placebo controlled, prospective single-center study. Adherence to treatment was assessed using the Morisky-Green scale 4 and 12 weeks after the start of treatment. Satisfaction with the treatment was assessed using the abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9). The severity of psoriasis was assessed on the mIGA and PGA scales, and the impact on quality of life was assessed using the PDI and DLQI scales. Results: A total of 65 patients entered the study. Adherence to treatment was good, with 73.8% of patients showing high adherence at 12 weeks. Satisfaction was also good, with 46 patients (70.8%) being completely satisfied. Conclusions: Over a 4-week period, patients treated with Cal/BD aerosol foam had significant improvement in disease severity that was directly related to treatment adherence. Francisco J. Navarro-TriviñoMario Lozano-LozanoRicardo Ruiz-VillaverdeMattioli1885articleadherencesatisfactioncalcipotriol/bethamethasoneaersolo foampsoriasisDermatologyRL1-803ENDermatology Practical & Conceptual (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	adherence satisfaction calcipotriol/bethamethasone aersolo foam psoriasis Dermatology RL1-803
spellingShingle	adherence satisfaction calcipotriol/bethamethasone aersolo foam psoriasis Dermatology RL1-803 Francisco J. Navarro-Triviño Mario Lozano-Lozano Ricardo Ruiz-Villaverde Calcipotriol/Betamethasone Dipropionate Aerosol Foam for Plaque Psoriasis: A Prospective, Observational, Non-Interventional, Single-Center Study of Patient Adherence and Satisfaction in Daily Use
description	Background: Psoriasis is a chronic inflammatory disease that has a negative impact on patients' quality of life. Patients with mild–moderate psoriasis can be treated with topical medications, such as the combination drug calcipotriol/betamethasone dipropionate (Cal/BD). Objectives: This study investigated the adherence of psoriasis patients to therapy with Cal/BD aerosol foam, as well as their satisfaction with the treatment’s efficacy, safety, and effect on their quality of life. Methods: Patients with mild–moderate plaque psoriasis were eligible to participate in this open-label, non-placebo controlled, prospective single-center study. Adherence to treatment was assessed using the Morisky-Green scale 4 and 12 weeks after the start of treatment. Satisfaction with the treatment was assessed using the abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9). The severity of psoriasis was assessed on the mIGA and PGA scales, and the impact on quality of life was assessed using the PDI and DLQI scales. Results: A total of 65 patients entered the study. Adherence to treatment was good, with 73.8% of patients showing high adherence at 12 weeks. Satisfaction was also good, with 46 patients (70.8%) being completely satisfied. Conclusions: Over a 4-week period, patients treated with Cal/BD aerosol foam had significant improvement in disease severity that was directly related to treatment adherence.
format	article
author	Francisco J. Navarro-Triviño Mario Lozano-Lozano Ricardo Ruiz-Villaverde
author_facet	Francisco J. Navarro-Triviño Mario Lozano-Lozano Ricardo Ruiz-Villaverde
author_sort	Francisco J. Navarro-Triviño
title	Calcipotriol/Betamethasone Dipropionate Aerosol Foam for Plaque Psoriasis: A Prospective, Observational, Non-Interventional, Single-Center Study of Patient Adherence and Satisfaction in Daily Use
title_short	Calcipotriol/Betamethasone Dipropionate Aerosol Foam for Plaque Psoriasis: A Prospective, Observational, Non-Interventional, Single-Center Study of Patient Adherence and Satisfaction in Daily Use
title_full	Calcipotriol/Betamethasone Dipropionate Aerosol Foam for Plaque Psoriasis: A Prospective, Observational, Non-Interventional, Single-Center Study of Patient Adherence and Satisfaction in Daily Use
title_fullStr	Calcipotriol/Betamethasone Dipropionate Aerosol Foam for Plaque Psoriasis: A Prospective, Observational, Non-Interventional, Single-Center Study of Patient Adherence and Satisfaction in Daily Use
title_full_unstemmed	Calcipotriol/Betamethasone Dipropionate Aerosol Foam for Plaque Psoriasis: A Prospective, Observational, Non-Interventional, Single-Center Study of Patient Adherence and Satisfaction in Daily Use
title_sort	calcipotriol/betamethasone dipropionate aerosol foam for plaque psoriasis: a prospective, observational, non-interventional, single-center study of patient adherence and satisfaction in daily use
publisher	Mattioli1885
publishDate	2021
url	https://doaj.org/article/784adb0dd8e64114a30eb4830d985e78
work_keys_str_mv	AT franciscojnavarrotrivino calcipotriolbetamethasonedipropionateaerosolfoamforplaquepsoriasisaprospectiveobservationalnoninterventionalsinglecenterstudyofpatientadherenceandsatisfactionindailyuse AT mariolozanolozano calcipotriolbetamethasonedipropionateaerosolfoamforplaquepsoriasisaprospectiveobservationalnoninterventionalsinglecenterstudyofpatientadherenceandsatisfactionindailyuse AT ricardoruizvillaverde calcipotriolbetamethasonedipropionateaerosolfoamforplaquepsoriasisaprospectiveobservationalnoninterventionalsinglecenterstudyofpatientadherenceandsatisfactionindailyuse
_version_	1718425806265384960

Calcipotriol/Betamethasone Dipropionate Aerosol Foam for Plaque Psoriasis: A Prospective, Observational, Non-Interventional, Single-Center Study of Patient Adherence and Satisfaction in Daily Use

Ejemplares similares